Efficacy and Safety of an Anti-nerve Growth Factor Antibody (Frunevetmab) for the Treatment of Degenerative Joint Disease-Associated Chronic Pain in Cats: A Multisite Pilot Field Study.

Front Vet Sci · 2021 · PMC8195238 · PMID 34124212

Europe PMC DOI

hedged sentence

0.0637

closest p · 1.3× alpha

0.0637

boldest claim

The sentences

approached significancep = 0.0637so close (0.05 < p ≤ 0.1)

Overall, there is a clear visual separation of the combined frunevetmab-treated group from the placebo-treated group and the main treatment effect approached significance ( p = 0.0637).

also in 8,237 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.